An
tax on medical devices is falling short of its revenue target because thousands of companies aren't paying it, according to a government audit released Tuesday.
The audit by the Treasury inspector general for tax administration says the IRS needs to do a better job policing the tax. The tax agency, however, doesn't have adequate tools to identify which companies owe it, the audit said.
The report could add fuel to efforts to repeal the tax, which is opposed by Republicans and many Democrats.
While the IRS has taken steps to educate companies about the tax, the agency "faces challenges to definitively identify manufacturers subject to the medical device excise tax reporting and payment requirements," said the inspector general, J. Russell George.
Source: ModernHealthcare
Read the full story:
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Similar In-Hospital, Long-Term Survival Rates Found Among Male, Female Patients With AECOPD
March 18th 2024This study analyzed sex differences among patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), with findings indicating that female smokers experience worse hospital outcomes despite similar overall survival rates.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
AstraZeneca joins efforts to address high drug prices by capping out-of-pocket costs for its inhalers; Opill, the first OTC birth control pill, is now accessible through online sales; expansion prompts questions on the effectiveness and regulation of remote monitoring technology.
Read More